Tianyin Biotechnology

Founded in 2016 and based in Shanghai, China, Tianyin Biotechnology originated as a scientific research spin-off from Shanghai Jiao Tong University. The company focuses on translating neuroscience and biomedical research into clinical applications, addressing the lack of objective biomarkers for psychiatric disorders. Tianyin Biotechnology provides objective testing technologies and diagnostic tools for psychiatric and psychological conditions. Its proprietary NSR testing system enables clinicians to detect early biological indicators of mental disorders, assess treatment responses, and guide personalized therapeutic interventions for depression and related conditions.

The company generates revenue from the development and commercialization of diagnostic instruments and reagents, clinical testing services, and partnerships with healthcare institutions for the integration of its NSR technology into mental health diagnostics and treatment systems. In October 2025, Tianyin Biotechnology closed a venture funding from new investor Shanghai STVC Group.